heart transplant
CareDx Q4 Revenues Up 64 Percent
The company reported $58.6 million in total revenues for the quarter and said testing services revenues rose 73 percent year over year.
Heart Transplant Cell-Free DNA Test Enables Earlier Detection of Acute Rejection Than Biopsy
Premium
The researchers hope that donor-derived cell-free DNA testing to monitor rejection can help relieve racial disparities in heart transplant outcomes.
CareDx Preliminary Q4 Revenues Up 63 Percent, Beat Estimates
CareDx expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.
CGS Administrators Aligns Medicare Coverage for CareDx AlloSure Tests
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
CareDx Q3 Revenues Up 58 Percent
The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.
Apr 30, 2020
CareDx Q1 Revenues Up 48 Percent
Feb 27, 2020
CareDx Q4 Revenues Up 52 Percent
Jan 22, 2020
Nov 19, 2019
Oct 31, 2019
CareDx Q3 Revenues Up 60 Percent
Aug 1, 2019
CareDx Q2 Revenues Up 76 Percent
May 8, 2019
CareDx Q1 Revenues Up 84 Percent
Mar 6, 2019
CareDx Q4 Revenues Increase 88 Percent
Feb 25, 2019
Nov 8, 2018